Aria Diagnostics published peer-reviewed data for a new noninvasive prenatal test that accurately detects Trisomy 21 and Trisomy 18 with improved efficiency. The technology offers significant improvement over existing approaches, enabling cost-effective and scalable analysis of cell-free DNA in maternal blood.
A landmark survey of 1,006 mothers found that only 24% discussed their decision to stop childbearing with their OB/GYNs. Women were largely unaware of non-surgical permanent birth control methods like the Essure procedure, which has a 99.8% effectiveness rate.
The MarginProbe System detected positive margins in 72% of cases, compared to 22% without the device, reducing patients' need for re-excision procedures. The technology improved traditional breast cancer surgery outcomes by providing immediate feedback on excised tissues.
PSD502 demonstrates significant time to ejaculation and ejaculatory control improvements, with a 5.5-fold increase in IELT, compared to placebo. Men treated with PSD502 experience reduced premature ejaculation symptoms and increased satisfaction.
A pivotal study has shown that PSD502 delays ejaculatory latency and improves sexual satisfaction in men with premature ejaculation. The treatment, a proprietary formulation of lidocaine and prilocaine, was well-tolerated and produced significant improvements in patient-reported outcomes.
A comprehensive review of medical literature by experts found no evidence supporting beneficial effects from blood transfusions. Studies show associations with higher rates of complications like heart attack, stroke, and kidney failure, highlighting the need for restricted practice and safer storage methods.
A five-year study will evaluate the performance of chest X-ray CAD in identifying hard-to-detect lung cancers, aiming to improve patient survival rates. The study, funded by the State of Ohio, will involve 9,000 test subjects and assess the software's ability to identify actionable pulmonary nodules.
A Phase 2 study showed ALO-01, an extended-release morphine sulfate plus sequestered naltrexone, provided similar effectiveness and tolerability to KADIAN Capsules for moderate-to-severe chronic osteoarthritis pain. The majority of patients rated both medications as good or excellent.
A six-month study demonstrated that bifeprunox maintained stability and displayed a favorable weight and lipid profile compared to placebo in patients with schizophrenia. The treatment also showed promising results in reducing the risk of deterioration over time.
The AlloMap test has been shown to correlate with oxygen saturation levels, cardiac filling pressures, and the electrical properties of the transplanted heart. Non-invasive blood tests can also detect cytomegalovirus-induced immune responses in lung transplant patients.
The study demonstrated similar release characteristics of the product to those found in previous studies of Alpharma's currently marketed KADIAN Capsules. The company is targeting an NDA filing for its abuse-deterrent product in the first half of 2008.
Bifeprunox demonstrates a favorable weight and lipid profile, comparable to placebo, in patients with stable schizophrenia. The treatment also showed decreases in body weight and minor reductions in BMI in patients with acute exacerbations of schizophrenia.
A Phase IV study found that Kadian's extended-release mechanism is maintained even in the presence of significant amounts of alcohol. The concomitant use of tested levels of alcohol with Kadian has no significant impact on morphine blood levels or release timing.
Sequenom's Fetal Nucleic Acid Technology shows promise in detecting fetal DNA in maternal blood, potentially diagnosing genetic defects early in pregnancy. This approach could benefit all expectant mothers, particularly those with high-risk pregnancies.
A study analyzed 227 adult patients with neck pain who participated in a larger prospective, randomized, open-label study. After four weeks, patients reported a 30.7% reduction in pain intensity, suggesting that Kadian offers broad utility for even the most disabling types of chronic pain.
A pilot study found that Cenestin reduced hot flashes and night sweats in post-menopausal women by 79% and improved overall sleep quality. The study also showed a significant reduction in galvanic skin responses, indicating better sweat gland activity.
The KRONUS-MSP trial found that switching to sustained-release opioid Kadian improves pain relief and quality of life, while reducing the need for medication. Patients who previously exceeded recommended doses of OxyContin or MS Contin found relief with Kadian.